Related references
Note: Only part of the references are listed.N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-gamma induced PD-L1 expression
Samir Mehndiratta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment
Navdeep Kaur et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells
Kuojun Zhang et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Yahui Huang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
Shipeng He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors, with potent in vitro and in vivo anticancer activity
Chunhui Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo
Ritu Ojha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
Xu-Wen Guan et al.
CELL DEATH & DISEASE (2020)
Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors
Ning-Yu Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1
Ehab Ghazy et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells
Zhaoping Pan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
Ashish Thakur et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma
Yi Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis
Guiyan Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors
Kunal Nepali et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression (vol 185, 111725, 2020)
Samir Mehndiratta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent
Qifu Xu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Role of tubulin acetylation in cellular functions and diseases
Yoko Nekooki-Machida et al.
MEDICAL MOLECULAR MORPHOLOGY (2020)
Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors
Hao Hu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
Jiangying Cao et al.
MOLECULES (2020)
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies
Xuewu Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases
Kehui Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Efficacy of Vinorelbine Monotherapy as Third- or Further-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
Hyun Kang et al.
ONCOLOGY (2019)
Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors
Belgin Sever et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
HDAC Inhibitors in Acute Myeloid Leukemia
Edurne San Jose-Eneriz et al.
CANCERS (2019)
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase
Mei-Jung Lai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides
Alberto Bresciani et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Next-generation of selective histone deacetylase inhibitors
Feifei Yang et al.
RSC ADVANCES (2019)
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC
Ritu Ojha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis, and biological evaluation of novel amide and hydrazide based thioether analogs targeting Histone deacteylase (HDAC) enzymes
Ayman B. Farag et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections
Yahui Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
Jie Zang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status
Xiaoyang Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4
Diana Lamaa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
Shipeng He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
Nilambra Dogra et al.
SCIENTIFIC REPORTS (2018)
Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors
Chen Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms
Kunal Nepali et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors
Guoqiang Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
Lianbin Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Chidamide in the treatment of peripheral T-cell lymphoma
Thomas S. Chan et al.
ONCOTARGETS AND THERAPY (2017)
Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
Mohamed D. M. Traore et al.
ACS OMEGA (2017)
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia
Jesse J. McClure et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
Xianping Lu et al.
INTRACTABLE & RARE DISEASES RESEARCH (2016)
Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
Histone deacetylases: structural determinants of inhibitor selectivity
Carmina Micelli et al.
DRUG DISCOVERY TODAY (2015)
Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors
Yanyang Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit
Charles M. Marson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors
Marije Slingerland et al.
ANTI-CANCER DRUGS (2014)
Indole-3-ethylsulfamoylphenylacrylamides: Potent histone deacetylase inhibitors with anti-inflammatory activity
Samir Mehndiratta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells
Y. Zhu et al.
ONCOGENE (2014)
Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a N-(2-Aminophenyl)benzamide Binding Unit
Charles M. Marson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Entinostat for treatment of solid tumors and hematologic malignancies
Jeffrey Knipstein et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer
Nan-Soon Wong et al.
PHARMACOGENETICS AND GENOMICS (2011)
Vinorelbine for non-small cell lung cancer
Maria Carmela Piccirillo et al.
EXPERT OPINION ON DRUG SAFETY (2010)
A pharmacogenetic study of vorinostat glucuronidation
Soonmo Peter Kang et al.
PHARMACOGENETICS AND GENOMICS (2010)
Histone deacetylase inhibitors that target tubulin
Joerg Schemies et al.
CANCER LETTERS (2009)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction
El-Sayed K. Assem et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2008)
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
C. James Chou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Marielle Fournel et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
Xiaozhong Qian et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Discovery and development of SAHA as an anticancer agent
P. A. Marks
ONCOGENE (2007)
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates
Cyril Boyault et al.
GENES & DEVELOPMENT (2007)
MS-275, a potent orally available inhibitor of histone deacetylases - The development of an anticancer agent
Holger Hess-Stumpp et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Toward selective histone deacetylase inhibitor design: Homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases
DF Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
RW Johnstone
NATURE REVIEWS DRUG DISCOVERY (2002)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
